# Accuray Inc: overview ARAY · Nasdaq · CIK 1138723 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/aray.md) · [Financials](/companies/aray/financials.md) · [Filings](/companies/aray/filings.md) · [Insiders](/companies/aray/insiders.md) Latest reported revenue: [$100.9m](/filings/0001437749-26-029098.md) for Q4 FY2026, three months to 2026-06-30, from the 10-K filed Aug 27, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-029098). ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [102](/filings/0001437749-26-004220.md) | [116](/filings/0001437749-26-004221.md) | [113](/filings/0001437749-26-015199.md) | [128 d](/filings/0001437749-26-029098.md) | [93.9](/filings/0001437749-26-004220.md) | [102](/filings/0001437749-26-004221.md) | [105](/filings/0001437749-26-015199.md) | [101 d](/filings/0001437749-26-029098.md) | | Gross margin | % | [33.9%](/filings/0001437749-26-004220.md) | [36.1%](/filings/0001437749-26-004221.md) | [27.9%](/filings/0001437749-26-015199.md) | [30.6% d](/filings/0001437749-26-029098.md) | [28.3%](/filings/0001437749-26-004220.md) | [23.5%](/filings/0001437749-26-004221.md) | [24.1%](/filings/0001437749-26-015199.md) | [34.8% d](/filings/0001437749-26-029098.md) | | Operating margin | % | [(2.1%)](/filings/0001437749-26-004220.md) | [4.1%](/filings/0001437749-26-004221.md) | [0.9%](/filings/0001437749-26-015199.md) | [3.3% d](/filings/0001437749-26-029098.md) | [(12.0%)](/filings/0001437749-26-004220.md) | [(11.3%)](/filings/0001437749-26-004221.md) | [(8.7%)](/filings/0001437749-26-015199.md) | [5.5% d](/filings/0001437749-26-029098.md) | | Net margin | % | [(3.9%)](/filings/0001437749-26-015199.md) | [2.2%](/filings/0001437749-26-015199.md) | [(1.1%)](/filings/0001437749-26-015199.md) | [0.9% d](/filings/0001437749-26-029098.md) | [(23.1%)](/filings/0001437749-26-015199.md) | [(13.5%)](/filings/0001437749-26-015199.md) | [(11.3%)](/filings/0001437749-26-015199.md) | [(1.9%) d](/filings/0001437749-26-029098.md) | | Diluted EPS | $ per share | [(0.04)](/filings/0001193125-25-266985.md) | [0.02](/filings/0001437749-26-004221.md) | [(0.01)](/filings/0000950170-25-062744.md) | not reported | [(0.18)](/filings/0001193125-25-266985.md) | [(0.11)](/filings/0001437749-26-004221.md) | not reported | not reported | | Free cash flow | $m | [(8.4)](/filings/0001437749-26-004220.md) | [0.9 d](/filings/0001437749-26-004221.md) | [17.1 d](/filings/0001437749-26-015199.md) | [(11.0) d](/filings/0001437749-26-029098.md) | [10.3](/filings/0001437749-26-004220.md) | [(19.0) d](/filings/0001437749-26-004221.md) | [(6.1) d](/filings/0001437749-26-015199.md) | [2.0 d](/filings/0001437749-26-029098.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [430](/filings/0000950170-24-108118.md) | [448](/filings/0000950170-24-108118.md) | [447](/filings/0001437749-26-004219.md) | [459](/filings/0001437749-26-029098.md) | [402](/filings/0001437749-26-029098.md) | | Gross margin | % | [37.2%](/filings/0000950170-24-108118.md) | [34.4%](/filings/0000950170-24-108118.md) | [32.0%](/filings/0001437749-26-004219.md) | [32.1%](/filings/0001437749-26-029098.md) | [27.7%](/filings/0001437749-26-029098.md) | | Operating margin | % | [1.9%](/filings/0000950170-24-108118.md) | [0.5%](/filings/0000950170-24-108118.md) | [0.1%](/filings/0001437749-26-004219.md) | [1.7%](/filings/0001437749-26-029098.md) | [(6.6%)](/filings/0001437749-26-029098.md) | | Net margin | % | [(1.2%)](/filings/0000950170-24-108118.md) | [(2.1%)](/filings/0000950170-24-108118.md) | [(3.5%)](/filings/0001437749-26-004219.md) | [(0.3%)](/filings/0001437749-26-029098.md) | [(12.2%)](/filings/0001437749-26-029098.md) | | Diluted EPS | $ per share | [(0.06)](/filings/0000950170-24-108118.md) | [(0.10)](/filings/0000950170-24-108118.md) | [(0.16)](/filings/0001193125-25-191242.md) | [(0.02)](/filings/0001193125-25-191242.md) | not reported | | Free cash flow | $m | [(7.1)](/filings/0000950170-24-108118.md) | [2.9](/filings/0000950170-24-108118.md) | [(15.5)](/filings/0001437749-26-004219.md) | [(1.4)](/filings/0001437749-26-029098.md) | [(12.8)](/filings/0001437749-26-029098.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/aray/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [TCW GROUP INC](/funds/850401.md) | 2026-06-30 | $4.1m | 18,942,059 | | Added +3,474,107 | | [NEUBERGER BERMAN GROUP LLC](/funds/1465109.md) | 2026-06-30 | $1.6m | 6,073,663 | | Added +218,599 | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $1.5m | 5,736,000 | | Added +100,000 | | [WEBER CAPITAL MANAGEMENT LLC /ADV](/funds/1099905.md) | 2026-06-30 | $1.3m | 4,932,706 | | Reduced −122,588 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.1m | 4,437,800 | | Added +7,408 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $842.0k | 3,266,185 | | Reduced −5,192,224 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $701.0k | 2,719,032 | | Added +2,101,555 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $551.6k | 2,139,720 | | New +2,139,720 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $532.4k | 2,065,284 | | Reduced −225,700 | | [DAFNA Capital Management LLC](/funds/1389933.md) | 2026-06-30 | $433.2k | 1,680,508 | | Unchanged | ## Recent filings [All 1,322 filings](/companies/aray/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 16:33 ET | [DEF 14A](/filings/0001140361-26-039918.md) | Proxy statement, period 2026-11-19 | 0001140361-26-039918 | | 2026-10-13 | 16:03 ET | [8-K](/filings/0001437749-26-032558.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001437749-26-032558 | | 2026-10-06 | 16:02 ET | [8-K](/filings/0001437749-26-032174.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-032174 | | 2026-09-02 | 20:00 ET | [SCHEDULE 13D/A](/filings/0001104659-26-104846.md) | Ownership report, active investor, amended | 0001104659-26-104846 | | 2026-08-27 | 16:02 ET | [10-K](/filings/0001437749-26-029098.md) | Annual report, period 2026-06-30 | 0001437749-26-029098 | | 2026-08-24 | 16:02 ET | [DEF 14A](/filings/0001140361-26-034187.md) | Proxy statement, period 2026-10-06 | 0001140361-26-034187 | | 2026-08-19 | 16:04 ET | [8-K](/filings/0001437749-26-028532.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-028532 | | 2026-08-06 | 16:01 ET | [8-K](/filings/0001437749-26-026250.md) | 3.01 Delisting notice | 0001437749-26-026250 | | 2026-07-29 | 17:25 ET | [8-K](/filings/0001437749-26-024904.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-024904 | | 2026-06-04 | 16:02 ET | [8-K](/filings/0001437749-26-019558.md) | 1.02 Termination of a material agreement; 7.01 Regulation FD disclosure | 0001437749-26-019558 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001437749-26-029098.md), filed Aug 27, 2026. ## Forecast league Q1 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/a02c606e-be45-486d-9e1e-0e22c37244a8) ## About the filer - CIK: 1138723 - Tickers: ARAY - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:06 ET. No prices; not investment advice.